Impact of prior primary tumor resection on long-term prognosis in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: a multicenter analysis - PubMed
an hour ago
- #cytoreductive nephrectomy
- #renal cell carcinoma
- #nivolumab ipilimumab
- Prior primary tumor resection (cytoreductive nephrectomy) is associated with significantly longer progression-free survival (PFS) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab plus ipilimumab, regardless of synchronous or metachronous metastasis.
- In a multicenter retrospective analysis with 54-month median follow-up, patients without prior primary resection (synchronous/CN(-) group) had median PFS of 6 months and OS of 22 months, worse than those with resection (metachronous: 18-month PFS, OS not reached; synchronous/CN(+): 19-month PFS, 52-month OS).
- Multivariable analysis confirmed absence of prior primary site resection as an independent risk factor for shorter PFS and OS, while objective response and disease control rates were highest in the metachronous group.